Ching‐Hon Pui
A5018363328- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Glioma Diagnosis and Treatment
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Cancer-related cognitive impairment studies
- Cancer therapeutics and mechanisms
- Adolescent and Pediatric Healthcare
- Lung Cancer Research Studies
- DNA Repair Mechanisms
- Genomics and Rare Diseases
- Immune Cell Function and Interaction
- Pharmaceutical studies and practices
- Methemoglobinemia and Tumor Lysis Syndrome
- Bone and Joint Diseases
- Folate and B Vitamins Research
- Neonatal Health and Biochemistry
St. Jude Children's Research Hospital
2016-2025
University of Tennessee Health Science Center
2015-2024
American Cancer Society
2003-2021
PharmacoGenetics (China)
2021
Tennessee Oncology
2002-2020
John Wiley & Sons (United States)
2020
Children's Hospital
2019
National Cancer Institute
2018
Stony Brook University
2012-2018
Juno Therapeutics (Germany)
2018
Early T-cell precursor acute lymphoblastic leukaemia (ETP ALL) is an aggressive malignancy of unknown genetic basis. We performed whole-genome sequencing 12 ETP ALL cases and assessed the frequency identified somatic mutations in 94 cases. was characterized by activating genes regulating cytokine receptor RAS signalling (67% cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 BRAF), inactivating lesions disrupting haematopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1 EP300)...
Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses identified high frequency DNA copy-number abnormalities in ALL, but the prognostic implications these not been defined.We studied cohort 221 children high-risk B-cell-progenitor ALL use single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing samples obtained at diagnosis. Children known very-high-risk subtypes (i.e.,...
Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, alterations lymphoid transcription factor genes, and poor outcome. The frequency spectrum genetic in Ph-like ALL its responsiveness tyrosine kinase inhibition are undefined, especially adolescents adults.
The prevalence and spectrum of predisposing mutations among children adolescents with cancer are largely unknown. Knowledge such may improve the understanding tumorigenesis, direct patient care, enable genetic counseling patients families.In 1120 younger than 20 years age, we sequenced whole genomes (in 595 patients), exomes 456), or both 69). We analyzed DNA sequences 565 genes, including 60 that have been associated autosomal dominant cancer-predisposition syndromes, for presence germline...
PURPOSE To define more uniform criteria for risk-based treatment assignment children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of National Institute (NCI) sponsored a workshop in September 1993. Participants included representatives from Childrens Group (CCG), Pediatric Oncology (POG), Dana-Farber (DFCI), St Jude Children's Research Hospital (SJCRH), and CTEP. METHODS Workshop participants presented reviewed data ALL clinical trials, using weighted...
Treatment of cancer with the epipodophyllotoxins (etoposide and teniposide) has been linked to development acute myeloid leukemia (AML) in children adults, but factors that might influence risk this complication therapy are poorly defined. We therefore assessed importance potential for secondary AML 734 consecutive lymphoblastic who attained complete remission received continuation (maintenance) treatment according different schedules epipodophyllotoxin administration.
BACKGROUND: Patients with acute lymphoblastic leukemia are often treated 6-mercaptopurine, and those homozygous deficiency in thiopurine S -methyltransferase (TPMT) enzyme activity have an extreme sensitivity to this drug as a result of the accumulation higher cellular concentrations thioguanine nucleotides. We studied metabolism, dose requirements, tolerance 6-mercaptopurine among patients different TPMT phenotypes. METHODS: compared, by use statistical modeling, pharmacology 180 who...
Childhood acute lymphoblastic leukemia (ALL) is curable with chemotherapy in approximately 80 percent of patients. However, the cause treatment failure remaining 20 patients largely unknown.We tested cells from 173 children for sensitivity vitro to prednisolone, vincristine, asparaginase, and daunorubicin. The were then subjected an assessment gene expression use 14,500 probe sets identify differentially expressed genes drug-sensitive drug-resistant ALL. Gene-expression patterns that...